FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Agios Pharmaceuticals
a public American pharmaceutical company
Related events
- FDA placed a clinical hold on RGX-121 trials, leading to a sharp decline in REGENXBIO Inc.'s stock price.
- FDA raised concerns over cell therapy evidence for Capricor Therapeutics, causing a sharp drop in stock price.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
Coverage
Newest first; wire copies grouped- Investing.comAgios shares drop after report notes deaths of Pyrukynd patients Investing.com -- Agios Pharmaceuticals stock is falling 15% in premarket trading Monday after the FDA’s Adverse Events Reporting Syste